L-Carnitine-supplementation in advanced pancreatic cancer (CARPAN) - a randomized multicentre trial
Tóm tắt
Cachexia, a >10% loss of body-weight, is one factor determining the poor prognosis of pancreatic cancer. Deficiency of L-Carnitine has been proposed to cause cancer cachexia. We screened 152 and enrolled 72 patients suffering from advanced pancreatic cancer in a prospective, multi-centre, placebo-controlled, randomized and double-blinded trial to receive oral L-Carnitine (4 g) or placebo for 12 weeks. At entry patients reported a mean weight loss of 12 ± 2,5 (SEM) kg. During treatment body-mass-index increased by 3,4 ± 1,4% under L-Carnitine and decreased (−1,5 ± 1,4%) in controls (p < 0,05). Moreover, nutritional status (body cell mass, body fat) and quality-of-life parameters improved under L-Carnitine. There was a trend towards an increased overall survival in the L-Carnitine group (median 519 ± 50 d versus 399 ± 43 d, not significant) and towards a reduced hospital-stay (36 ± 4d versus 41 ± 9d,n.s.). While these data are preliminary and need confirmation they indicate that patients with pancreatic cancer may have a clinically relevant benefit from the inexpensive and well tolerated oral supplementation of L-Carnitine.
Tài liệu tham khảo
Rocha-Lima CM: New directions in the management of advanced pancreatic cancer: a review. Anticancer Drugs. 2008, 19: 435-446. 10.1097/CAD.0b013e3282fc9d11.
Greenlee RT, Hill-Harmon MB, Murray T, Thun M: Cancer statistics, 2001. CA Cancer J Clin. 2001, 51: 15-36. 10.3322/canjclin.51.1.15.
DiMagno EP, Reber HA, Tempero MA: AGA technical review on the epidemiology, diagnosis, and treatment of pancreatic ductal adenocarcinoma. Americangastroenterological Association. gastroenterology. 1999, 117: 1464-1484.
Neoptolemos JP, Stocken DD, Bassi C, Ghaneh P, Cunningham D, Goldstein D, Padbury R, Moore MJ, Gallinger S, Mariette C, et al: Adjuvant chemotherapy with fluorouracil plus folinic acid vsgemcitabine following pancreatic cancer resection: a randomized controlled trial. JAMA. 2010, 304: 1073-1081. 10.1001/jama.2010.1275.
Bachmann J, Ketterer K, Marsch C, Fechtner K, Krakowski-Roosen H, Büchler MW, Friess H, Martignoni ME: Pancreatic cancer related cachexia: influence on metabolism and correlation to weight loss and pulmonary function. BMC Cancer. 2009, 9: 255-10.1186/1471-2407-9-255.
Pelzer U, Arnold D, Govercin M, Stieler J, Doerken B, Riess H, Oettle H: Parenteral nutrition support for patients with pancreatic cancer. Results of a phase II study. BMC Cancer. 2010, 10: 86-10.1186/1471-2407-10-86.
Uomog , Gallucci F, Rabitti PG: Anorexia-cachexia syndrome in pancreatic cancer: recent development in research and management. JOP. 2006, 7: 157-162.
Ockenga J, Valentini L: Review article: anorexia and cachexia in gastrointestinal cancer. Aliment Pharmacol Ther. 2005, 22: 583-594. 10.1111/j.1365-2036.2005.02628.x.
Bozzetti F: Screening the nutritional status in oncology: a preliminary report on 1,000 outpatients. Support Care Cancer. 2009, 17: 279-284. 10.1007/s00520-008-0476-3.
Cohen SJ, Pinoverw H, Watson JC, Meropol NJ: Pancreatic cancer. Curr Treat Options Oncol. 2000, 1: 375-386. 10.1007/s11864-000-0065-2.
Malaguarnera M, Risino C, Gargante MP, Tomasello AV, Costanzo M, Cannizzaro MA, Costanzo M, Cannizzaro MA: Decrease of serum carnitine levels in patients with or without gastrointestinal cancer cachexia. World Jgastroenterol. 2006, 12: 4541-4545.
Graziano F, Bisonni R, Catalano V, Silva R, Rovidati S, Mencarini E, Ferraro B, Canestrari F, Baldelli AM, Deg A, et al: Potential role of levocarnitine supplementation for the treatment of chemotherapy-induced fatigue in non-anaemic cancer patients. Br J Cancer. 2002, 86: 1854-1857. 10.1038/sj.bjc.6600413.
Stone P, Richardson A, Ream E, Smith AG, Kerr DJ, Kearney N: Cancer-related fatigue: inevitable, unimportant and untreatable? Results of a multi-centre patient survey. Cancer Fatigue Forum. Ann Oncol. 2000, 11: 971-975.
Schwartz AL, Nail LM, Chen S, Meek P, Barsevick AM, King ME, Jones LS: Fatigue patterns observed in patients receiving chemotherapy and radiotherapy. Cancer Invest. 2000, 18: 11-19. 10.3109/07357900009023057.
Zaugg K, Yao Y, Reilly PT, Kannan K, Kiarash R, Mason J, Huang P, Sawyer SK, Fuerth B, Faubert B, et al: Carnitine palmitoyltransferase 1 C promotes cell survival and tumorgrowth under conditions of metabolic stress. Genes Dev. 2011, 25: 1041-51. 10.1101/gad.1987211.
Liu S, Zhang ZQ, Chen Q, Liu B, Wu JP, Zhu L: L-Carnitine ameliorates cancer cachexia in mice by regulating the expression and activity of carnitine palmityl transferase. Cancer Biol Ther. 2011, 12: 125-30. 10.4161/cbt.12.2.15717.
Kodo N, Millington DS, Norwood DL, Roe CR: Quantitative assay of free and total carnitine using tandem mass spectrometry. Clin Chim Acta. 1990, 186: 383-390. 10.1016/0009-8981(90)90324-L.
Rebouche CJ: Carnitine function and requirements during the life cycle. FASEB J. 1992, 6: 3379-3386.
Bosy-Westphal A, Danielzik S, Dorhofer RP, Later W, Wiese S, Muller MJ: Phase angle from bioelectrical impedance analysis: population reference values by age, sex, and body mass index. JPEN J Parenter Enteral Nutr. 2006, 30: 309-316. 10.1177/0148607106030004309.
Fitzsimmons D, Johnson CD, George S, Payne S, Sandberg AA, Bassi C, Beger HG, Birk D, Buchler MW, Dervenis C, et al: Development of a disease specific quality of life (QoL) questionnaire module to supplement the EORTC core cancer QoL questionnaire, the QLQ-C30 in patients with pancreatic cancer. EORTC Study group on Quality of Life. Eur J Cancer. 1999, 35: 939-941. 10.1016/S0959-8049(99)00047-7.
Radbruch L, Sabatowski R, Elsner F, Everts J, Mendoza T, Cleeland C: Validation of thegerman version of the brief fatigue inventory. J Pain Symptom Manage. 2003, 25: 449-458. 10.1016/S0885-3924(03)00073-3.
Grazig G, Meriggioli M: Can the treatment with L-carnitine improve the inflammation in chronic hemo dialysis patients?. G Ital Nefrol. 2004, 21 (Suppl 30): S204-S207.
Nitenbergg , Raynard B: Nutritional support of the cancer patient: issues and dilemmas. Crit Rev Oncol Hematol. 2000, 34: 137-168. 10.1016/S1040-8428(00)00048-2.
Dodsonw L, Sachan DS, Krauss S, Hanna W: Alterations of serum and urinary carnitine profiles in cancer patients: hypothesis of possible significance. J Am Coll Nutr. 1989, 8: 133-142.
Mancinelli A, D'Iddio S, Bisonni R, Graziano F, Lippe P, Calvani M: Urinary excretion of L-carnitine and its short-chain acetyl-L-carnitine in patients undergoing carboplatin treatment. Cancer Chemother Pharmacol. 2007, 60: 19-26. 10.1007/s00280-006-0341-3.
Lancaster CS, Hu C, Franke RM, Filipski KK, Orwick SJ, Chen Z, Zuo Z, Loosw J, Sparreboom A: Cisplatin-induced down regulation of OCTN2 affects carnitine wasting. Clin Cancer Res. 2010, 16: 4789-4799. 10.1158/1078-0432.CCR-10-1239.
Lebrun C, Alchaar H, Candito M, Bourg V, Chatel M: Levocarnitine administration in multiple sclerosis patients with immunosuppressive therapy-induced fatigue. Mult Scler. 2006, 12: 321-324. 10.1191/135248506ms1275oa.
Cruciani RA, Dvorkin E, Homel P, Culliney B, Malamud S, Lapin J, Portenoy RK, Esteban-Cruciani N: L-carnitine supplementation in patients with advanced cancer and carnitine deficiency: a double-blind, placebo-controlled study. J Pain Symptom Manage. 2009, 37: 622-631. 10.1016/j.jpainsymman.2008.03.021.
Pisano C, Vesci L, Milazzo FM, Guglielmi MB, Fodera R, Barbarino M, D'Incalci M, Zucchetti M, Petrangolini G, Tortoreto M, et al: Metabolic approach to the enhancement of antitumor effect of chemotherapy: a key role of acetyl-L-carnitine. Clin Cancer Res. 2010, 16: 3944-3953. 10.1158/1078-0432.CCR-10-0964.
Haschke M, Vitins T, Lude S, Todesco L, Novakova K, Herrmann R, Krahenbuhl S: Urinary excretion of carnitine as a marker of proximal tubular damage associated with platin-based anti neo plastic drugs. Nephrol Dial Transplant. 2010, 25: 426-433. 10.1093/ndt/gfp456.
Burris HA, Moore MJ, Andersen J, Green MR, Rothenberg ML, Modiano MR, Cripps MC, Portenoy RK, Storniolo AM, Tarassoff P, et al: Improvements in survival and clinical benefit with gemcitabine as first line therapy for patients with advanced pancreas cancer a randomized trial. J Clin Oncol. 1997, 15: 2403-2413.